How the treatment of AML will change
Mary Frances McMullin
An overview of the current treatment landscape of non-Hodgkin lymphoma
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
How can standard risk multiple myeloma (MM) patients be cured?
Developments in prognostic factors of acute myeloid leukemia (AML)
Gert J. Ossenkoppele